Literature DB >> 8294630

High-dose intravenous magnesium sulfate in the management of life-threatening status asthmaticus.

M Sydow1, T A Crozier, S Zielmann, J Radke, H Burchardi.   

Abstract

In severe status asthmaticus basic medical treatment often fails to improve the patient's condition. Mechanical ventilation in this situation is associated with a high incidence of serious complications. After the bronchodilating effect of moderate-dose magnesium sulfate in asthmatic patients had been demonstrated in previous studies we treated five mechanically ventilated patients with refractory status asthmaticus successfully with high dosages of MgSO4 IV (10-20 g within 1 h depending on the bronchodilating effect). MgSO4 resulted in a significant decrease of peak airway pressure (43.0 +/- 6.8 to 32.0 +/- 8.0 cmH2O) and inspiratory flow resistance (22.7 +/- 7.0 to 11.9 +/- 6.0 cmH2O.l-1.s-1) within 1 h. The resulting serum magnesium levels after one hour were up to threefold of the normal serum levels. Although a maintainance dose of 0.4 g/h had been administered continuously during the following 24 h serum magnesium decreased towards normal values within this time. The only relevant side-effect was a mild to moderate arterial hypotension in two of the five patients during the high dose administration period of MgSO4 which responded readily to dopamine treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8294630     DOI: 10.1007/BF01711089

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

1.  Intravenous magnesium sulfate in acute asthma.

Authors:  W M Kufs
Journal:  JAMA       Date:  1990-01-26       Impact factor: 56.272

Review 2.  Excess magnesium.

Authors:  J P Mordes; W E Wacker
Journal:  Pharmacol Rev       Date:  1977-12       Impact factor: 25.468

3.  Treatment of status asthmaticus with intravenous magnesium sulfate.

Authors:  H Okayama; M Okayama; T Aikawa; M Sasaki; T Takishima
Journal:  J Asthma       Date:  1991       Impact factor: 2.515

4.  Effect of magnesium sulfate on bronchoconstriction in the lung periphery.

Authors:  K S Lindeman; C A Hirshman; A N Freed
Journal:  J Appl Physiol (1985)       Date:  1989-06

5.  Extreme hypermagnesemia as a cause of refractory hypotension.

Authors:  J P Mordes; R Swartz; R A Arky
Journal:  Ann Intern Med       Date:  1975-11       Impact factor: 25.391

6.  Mechanical ventilation in patients with acute severe asthma.

Authors:  J K Mansel; S W Stogner; M F Petrini; J R Norman
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

7.  Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma.

Authors:  M Noppen; L Vanmaele; N Impens; W Schandevyl
Journal:  Chest       Date:  1990-02       Impact factor: 9.410

8.  Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery.

Authors:  T A Crozier; J Radke; A Weyland; M Sydow; W Seyde; E Markakis; D Kettler
Journal:  Eur J Anaesthesiol       Date:  1991-03       Impact factor: 4.330

9.  Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department.

Authors:  E M Skobeloff; W H Spivey; R M McNamara; L Greenspon
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

  9 in total
  10 in total

Review 1.  Management of mechanical ventilation in acute severe asthma: practical aspects.

Authors:  Mauro Oddo; François Feihl; Marie-Denise Schaller; Claude Perret
Journal:  Intensive Care Med       Date:  2006-01-27       Impact factor: 17.440

2.  Use of intravenous magnesium sulfate for the treatment of an acute asthma exacerbation in pediatric patients.

Authors:  Suzannah Kokotajlo; Lisa Degnan; Rachel Meyers; Anita Siu; Christine Robinson
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

Review 3.  Pharmacologic treatment of the adult hospitalized asthma patient.

Authors:  M L Kreutzer; S Louie
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

4.  High-dose intravenous magnesium sulfate in the management of life-threatening status asthmaticus.

Authors:  F G Lemesle
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440

5.  Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.

Authors:  I Federico Fernandez Nievas; Kanwaljeet J S Anand
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

6.  A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.

Authors:  M M Huycke; M T Naguib; M M Stroemmel; K Blick; K Monti; S Martin-Munley; C Kaufman
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 7.  Drug therapy approaches in the treatment of acute severe asthma in hospitalised children.

Authors:  L K DeNicola; M O Gayle; K V Blake
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  Acute severe asthma: new approaches to assessment and treatment.

Authors:  Spyros A Papiris; Effrosyni D Manali; Likurgos Kolilekas; Christina Triantafillidou; Iraklis Tsangaris
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Stating the obvious: intravenous magnesium sulphate should be the first parenteral bronchodilator in paediatric asthma exacerbations unresponsive to first-line therapy.

Authors:  Gokul Erumbala; Sabu Anzar; Amjad Tonbari; Ramadan Salem; Colin Powell
Journal:  Breathe (Sheff)       Date:  2021-12

10.  Short and long term treatment of asthma with intravenous nutrients.

Authors:  Welman A Shrader
Journal:  Nutr J       Date:  2004-05-14       Impact factor: 3.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.